SENS Stock Price: Senseonics Holdings Inc soars as investors await pending FDA approval

NYSEAMERICAN:SENS surged by 27.71% on Monday amidst a rocky day in the markets.
An underwriter has valued shares at $1.925 each as Senseonics ramps up a public stock offering.
Senseonics awaits FDA approval for its diabetes technology.

Stocks Reporter FXStreet

NASDAQ:SENS has been a stock on fire lately as shares have already gained more than 235% since the beginning of January. On Monday, Senseonics Holdings added a further 27.71% to close the first trading session of the week at the price of $2.95. The recent surge has pushed the penny stock to levels over double its 50-day moving average and nearly six-fold over its 200-day moving average, which shows its rapidly ascending trajectory. The stock is trending back towards its 52-week high of $3.90 that it reached earlier this month.

There were a couple of catalysts that sent the little known diabetes treatment company skyrocketing on Monday. The first is an underwriter valuing shares of the company at $1.925 each as Senseonics works through the process of a public stock offering of over 51 million new shares. It is a common vehicle used by firms who have seen their stock price grow rapidly in a short amount of time. The second reason is that investors have growing optimism that Senseonics will find out if they are to receive FDA approval for its Eversense CGM System. There is anticipation that this decision will come in the first half of 2021.

SENS stock forecast

The Maryland-based company could see a further surge in its stock price if the FDA does give them its approval. The Eversense CGM System allows patients to constantly measure their glucose levels for periods of up to 90 days. Senseonics is also still riding the high of entering an agreement to have the cost of its equipment covered by EmblemHealth, one of the largest not for profit health plan providers in the United States.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Stocks Reporter

FXStreet

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

Editor's Picks

EUR/USD drops to daily lows near 1.1630

EUR/USD now loses some traction and slips back to the area of daily lows around 1.1630 on the back of a mild bounce in the US Dollar. Fresh US data, including the September PCE inflation numbers and the latest read on December consumer sentiment, didn’t really move the needle, so the pair is still on course to finish the week with a respectable gain.

GBP/USD trims gains, recedes toward 1.3320

GBP/USD is struggling to keep its daily advance, coming under fresh pressure and retreating to the 1.3320 zone following a mild bullish attempt in the Greenback. Even though US consumer sentiment surprised to the upside, the US Dollar isn’t getting much love, as traders are far more interested in what the Fed will say next week.

Gold makes a U-turn, back to $4,200

Gold is now losing the grip and receding to the key $4,200 region per troy ounce following some signs of life in the Greenback and a marked bounce in US Treasury yields across the board. The positive outlook for the precious metal, however, remains underpinned by steady bets for extra easing by the Fed.